Pharmavite acquires Bonafide Health, a women’s health brand that focuses on menopause support
Acquired for $425 million, Bonafide Health focuses on helping women manage their menopause with scientifically formulated products inspired by nature that are supported by clinical evidence and endorsed by healthcare practitioners.
Photo © AdobeStock.com/ insta_photos
Pharmavite LLC has announced the acquisition of Bonafide Health, expanding and complementing the company’s existing women’s health business, which is comprised of Uqora, and Equelle. Acquired for $425 million, Bonafide Health focuses on helping women manage their menopause with scientifically formulated products inspired by nature that are supported by clinical evidence and endorsed by healthcare practitioners. Its six core products include Revaree, Relizen, Ristela, Clairvee, Serenol, and The Silvessa System that deliver long-term, sustainable support for needs such as hot flashes, vaginal dryness, vaginal microbiome, and sexual satisfaction.
“Our steadfast commitment to science and innovation has allowed us to build something special at Bonafide Health and we’ve been looking for the right partner to grow the business and reach more women that need support. Pharmavite is that partner,” said Michael Satow co-founder and CEO of Bonafide Health, in a press release. “Pharmavite deeply understands the importance of the model we’ve built, from the rigorous scientific data that underpins our products, to the power of the work we do with the doctors and other health care providers who are having conversations with women across the country looking for better solutions.”
According to the company’s press release, Bonafide will continue to operate out of its current headquarters in Harrison, NY, and the acquisition will have no impact on the company’s workforce. Pharmavite was advised by Houlihan Lokey. William Hood & Company served as lead financial advisor and EVOLUTION Life Science Partners served as co-advisor to Bonafide Health in the transaction.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
